That's right. Well, we only have the one use so far of CAMR, and in that case it was a competitive price.
Part of the reason why we've seen the number of people on treatment go up is precisely because the generics have been available. The global fund money, for example, has been able to stretch that much further because you're paying 20¢ per tablet rather than five bucks a tablet. That's why we have 5.2 million people getting treatment now.
But as I was saying before, that source of Indian generics is now very much in question. And the tap is turning off because of these patent act changes. Now those changes were made in 2005. The drugs that were already being produced in generic form up to 2005 were grandfathered. So those are still able to be supplied. And because of where we are in the history of scaling up people onto AIDS treatment, it's still the case that the majority of people are on those first-line regiments, which are coming from Indian generic manufacturers.
What we're starting to see now, as Dr. Kilby was saying—and we will see more of it in the future—is that those first-line drugs are starting to fail for people as their virus mutates and develops resistance. So then they will need to switch onto second-line drugs and because India now has patent protection, these are the ones that are going to be patented in India. And so getting them in generic form from India is really very much an open question. We don't know how that's going to play out yet.